Citation: | Feifei Li, Youyang Shi, Mei Ma, Xiaojuan Yang, Xiaosong Chen, Ying Xie, Sheng Liu. Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100977 |
[1] |
R.L. Siegel, K.D. Miller, N.S. Wagle, et al., Cancer statistics, 2023, CA Cancer J. Clin. 73(2023) 17-48.
|
[2] |
S. Loibl, L. Gianni, HER2-positive breast cancer, Lancet 389(2017) 2415-2429.
|
[3] |
D.J. Slamon, B. Leyland-Jones, S. Shak, et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med. 344(2001) 783-792.
|
[4] |
C.S. Wynn, S.C. Tang, Anti-HER2 therapy in metastatic breast cancer: Many choices and future directions, Cancer Metastasis Rev. 41(2022) 193-209.
|
[5] |
K.S. Vega Cano, D.H. Marmolejo Castañeda, S. Escrivá-de-Romaní, et al., Systemic therapy for HER2-positive metastatic breast cancer: Current and future trends, Cancers 15(2022), 51.
|
[6] |
H. Kennecke, R. Yerushalmi, R. Woods, et al., Metastatic behavior of breast cancer subtypes, J. Clin. Oncol. 28(2010) 3271-3277.
|
[7] |
N. Harbeck, C.S. Huang, S. Hurvitz, et al., Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial, Lancet Oncol. 17(2016) 357-366.
|
[8] |
G. Nader-Marta, D. Martins-Branco, E. de Azambuja, How we treat patients with metastatic HER2-positive breast cancer, ESMO Open 7(2022), 100343.
|
[9] |
F. Li, S. Liu, Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer, Front. Immunol. 13(2022), 1083462.
|
[10] |
F.A.I. Ehlers, N.A. Beelen, M. van Gelder, et al., ADCC-inducing antibody trastuzumab and selection of KIR-HLA ligand mismatched donors enhance the NK cell anti-breast cancer response, Cancers 13(2021), 3232.
|
[11] |
R. Du, X. Zhang, X. Lu, et al., PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity, Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother. 68(2023), 100947.
|
[12] |
G.D. Rak, E.M. Mace, P.P. Banerjee, et al., Natural killer cell lytic granule secretion occurs through a pervasive actin network at the immune synapse, PLoS Biol. 9(2011), e1001151.
|
[13] |
X. Ren, M. Peng, P. Xing, et al., Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell-mediated antitumor immunity, J. Clin. Investig. 132(2022), e163620.
|
[14] |
B. Lipinski, P. Arras, L. Pekar, et al., NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats, Protein Sci. a Publ. Protein Soc. 32(2023), e4593.
|
[15] |
A. Glasner, H. Ghadially, C. Gur, et al., Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1, J. Immunol. Baltim. Md 1950188(2012) 2509-2515.
|
[16] |
L. Gauthier, A. Morel, N. Anceriz, et al., Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity, Cell 177(2019) 1701-1713.e16.
|
[17] |
P. Peng, Y. Lou, S. Wang, et al., Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy, J. Immunother. Cancer 10(2022), e005769.
|
[18] |
S. Vasu, S. He, C. Cheney, et al. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts, Blood 127(2016) 2879-2889.
|
[19] |
J. Xing, S. Liu, X. Tang, et al., Retrospective analysis of postoperative formula with additions and subtractions for the treatment of HER-2 overexpression breast cancer, Liaoning University of Traditional Chinese Medicine 24(2022) 112-120.
|
[20] |
G. Chen, Z. Cao, Z. Shi, et al., Microbiome analysis combined with targeted metabolomics reveal immunological anti-tumor activity of icariside I in a melanoma mouse model, Biomedecine Pharmacother. 140(2021), 111542.
|
[21] |
L. Song, X. Chen, L. Mi, et al., Icariin-induced inhibition of SIRT6/NF-κB triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer, Cancer Sci 111(2020) 4242-4256.
|
[22] |
S. Dandawate, L. Williams, N. Joshee, et al., Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity, Cancer Immunol. Immunother. 61(2012) 701-711.
|
[23] |
W. Li, Q. Xu, Y. He, et al., Anti-tumor effect of Steamed Codonopsis lanceolata in H22 tumor-bearing mice and its possible mechanism, Nutrients 7(2015) 8294-8307.
|
[24] |
F. Li, Y. Shi, Y. Zhang, et al., Investigating the mechanism of Xian-ling-Lian-Xia-Fang for inhibiting vasculogenic mimicry in triple negative breast cancer via blocking VEGF/MMPs pathway, Chin. Med. 17(2022), 44.
|
[25] |
J. Wu, F. Gao, C. Wang, et al., IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma, J. Exp. Clin. Cancer Res. 38(2019), 321.
|
[26] |
L. Li, T. Liu, L. Shi, et al., HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking, Theranostics 12(2022) 5551-5563.
|
[27] |
J. Scerri, C. Scerri, F. Schäfer-Ruoff, et al., PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer, Front. Endocrinol. 13(2022), 1010092.
|
[28] |
W. Li, J. Zhou, X. Wang, et al., CD49a+CD49b+ NK cells induced by viral infection reflect an activated state of conventional NK cells, Sci. China Life Sci. 63(2020) 1725-1733.
|
[29] |
L. Martinet, M.J. Smyth, Balancing natural killer cell activation through paired receptors, Nat. Rev. Immunol. 15(2015) 243-254.
|
[30] |
M.D. Miljkovic, S.P. Dubois, J.R. Müller, et al., Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies, Blood Adv. 7(2023) 384-394.
|
[31] |
F. Carrette, E. Vivier, NKG2A blocks the anti-metastatic functions of natural killer cells, Cancer Cell 41(2023) 232-234.
|
[32] |
G. Zheng, Z. Guo, W. Li, et al., Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab, Signal Transduct. Target. Ther. 6(2021), 236.
|
[33] |
J. Yang, A. Kumar, A.E. Vilgelm, et al., Loss of CXCR4 in myeloid cells enhances antitumor immunity and reduces melanoma growth through NK cell and FASL mechanisms, Cancer Immunol. Res. 6(2018) 1186-1198.
|
[34] |
K. Fousek, L.A. Horn, H. Qin, et al., An interleukin-15 superagonist enables antitumor efficacy of natural killer cells against all molecular variants of SCLC, J. Thorac. Oncol. 18(2023) 350-368.
|
[35] |
R.B. Delconte, T.B. Kolesnik, L.F. Dagley, et al., CIS is a potent checkpoint in NK cell-mediated tumor immunity, Nat. Immunol. 17(2016) 816-824.
|
[36] |
H. Zhu, R.H. Blum, D. Bernareggi, et al., Metabolic reprograming via deletion of CISH in human iPSC-derived NK cells promotes InVivo persistence and enhances anti-tumor activity, Cell Stem Cell 27(2020) 224-237.e6.
|
[37] |
D. Cameron, M.J. Piccart-Gebhart, R.D. Gelber, et al., 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial, Lancet 389(2017) 1195-1205.
|
[38] |
R. Ghosh, A. Narasanna, S.E. Wang, et al., Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers, Cancer Res. 71(2011) 1871-1882.
|
[39] |
H. Maadi, Z. Wang, A novel mechanism underlying the inhibitory effects of trastuzumab on the growth of HER2-positive breast cancer cells, Cells 11(2022), 4093.
|
[40] |
S. Chumsri, Advancing outcomes of metastatic HER2-positive breast cancer, Lancet 401(2023) 1746-1747.
|
[41] |
M. Shang, Y. Chi, J. Zhang, et al., The therapeutic effectiveness of neoadjuvant trastuzumab plus chemotherapy for HER2-positive breast cancer can be predicted by tumor-infiltrating lymphocytes and PD-L1 expression, Front. Oncol. 11(2021), 706606.
|
[42] |
S. Bruni, F.L. Mauro, C.J. Proietti, et al., Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression, J. Immunother. Cancer 11(2023), e005325.
|
[43] |
F. Meng, S. Zhang, J. Xie, et al., Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells, J. Hematol. Oncol. 16(2023), 62.
|
[44] |
L. Mecklenburg, B. Tychsen, R. Paus, Learning from nudity: Lessons from the nude phenotype, Exp. Dermatol. 14(2005) 797-810.
|
[45] |
J. Fogh, J.M. Fogh, T. Orfeo, One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice, J. Natl. Cancer Inst. 59(1977) 221-226.
|
[46] |
L.D. Shultz, F. Ishikawa, D.L. Greiner, Humanized mice in translational biomedical research, Nat. Rev. Immunol. 7(2007) 118-130.
|
[47] |
I. Szadvari, O. Krizanova, P. Babula, Athymic nude mice as an experimental model for cancer treatment, Physiol. Res. 65(2016) S441-S453.
|
[48] |
J. Lv, L. Qin, R. Zhao, et al., Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels, Mol. Ther. Oncolytics 28(2022) 46-58.
|
[49] |
F. Souza-Fonseca-Guimaraes, G.R. Rossi, L.F. Dagley, et al., TGFβ and CIS inhibition overcomes NK-cell suppression to restore antitumor immunity, Cancer Immunol. Res. 10(2022) 1047-1054.
|
[50] |
J. Bi, C. Huang, X. Jin, et al., TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells, J. Immunother. Cancer 11(2023), e006002.
|
[51] |
K.M. Maalej, M. Merhi, V.P. Inchakalody, et al., CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances, Mol. Cancer 22(2023), 20.
|
[52] |
R. Elahi, A.H. Heidary, K. Hadiloo, et al., Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects, Stem Cell Rev. Rep. 17(2021) 2081-2106.
|
[53] |
H. Ebrahimiyan, A. Tamimi, B. Shokoohian, et al., Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages, Int. Immunopharmacol. 106(2022), 108587.
|
[54] |
O. Cienfuegos-Jimenez, E. Vazquez-Garza, A. Rojas-Martinez, CAR-NK cells for cancer therapy: Molecular redesign of the innate antineoplastic response, Curr. Gene Ther. 22(2022) 303-318.
|
[55] |
B. Cao, M. Liu, L. Wang, et al., Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer, Biochem. Biophys. Res. Commun. 524(2020) 96-102.
|
[56] |
S. Klöß, O. Oberschmidt, M. Morgan, et al., Optimization of human NK cell manufacturing: Fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells, Hum. Gene Ther. 28(2017) 897-913.
|
[57] |
J. Tanaka, J.S. Miller, Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies, Blood Rev. 44(2020), 100678.
|
[58] |
I. Pedroza-Pacheco, A. Madrigal, A. Saudemont, Interaction between natural killer cells and regulatory T cells: Perspectives for immunotherapy, Cell. Mol. Immunol. 10(2013) 222-229.
|
[59] |
T.A. Waldmann, E. Lugli, M. Roederer, et al., Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques, Blood 117(2011) 4787-4795.
|
[60] |
T. Bald, M.F. Krummel, M.J. Smyth, et al., The NK cell-cancer cycle: Advances and new challenges in NK cell-based immunotherapies, Nat. Immunol. 21(2020) 835-847.
|
[61] |
C. Di Nitto, E. Gilardoni, J. Mock, et al., An engineered IFNγ-antibody fusion protein with improved tumor-homing properties, Pharmaceutics 15(2023), 377.
|
[62] |
Y. Miao, X. Fan, L. Wei, et al., Lizhong Decoction ameliorates pulmonary infection secondary to severe traumatic brain injury in rats by regulating the intestinal physical barrier and immune response, J. Ethnopharmacol. 311(2023), 116346.
|